Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 23.21% is 42% below its 5-year average of 39.89%, near the high end of its 5-year range (-220.77%–93.75%).
187.84% above its 12-month average of -26.42%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): -220.77%.
GROSS MARGIN
23.21%
GROSS MARGIN AVG TTM
-26.42%
GROSS MARGIN AVG 3Y
26.98%
GROSS MARGIN AVG 5Y
39.89%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+187.84%
CURRENT VS 3Y AVG
-13.98%
CURRENT VS 5Y AVG
-41.81%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-43.91%
vs the sector median at left
bioAffinity Technologies, Inc.
Market Cap
$2.54M
Gross Margin
23.21%
TTM Avg
-26.42%
3Y Avg
26.98%
5Y Avg
39.89%
Market Cap
$2.44M
Gross Margin
67.21%
TTM Avg
75.24%
3Y Avg
78.18%
5Y Avg
70.66%
Market Cap
$2.66M
Gross Margin
35.28%
TTM Avg
30.83%
3Y Avg
37.03%
5Y Avg
41.13%
Market Cap
$2.38M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$2.38M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$2.37M
Gross Margin
80.40%
TTM Avg
59.71%
3Y Avg
-452.13%
5Y Avg
-301.42%
Market Cap
$2.37M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | $2.54M | 23.21% | -26.42% | 26.98% | 39.89% |
| Nuwellis, Inc. (NUWE)vs › | $2.56M | 69.69% | 64.31% | 60.13% | 58.62% |
| Jaguar Health, Inc. (JAGX)vs › | $2.44M | 67.21% | 75.24% | 78.18% | 70.66% |
| Universe Pharmaceuticals Inc. (UPC)vs › | $2.66M | 35.28% | 30.83% | 37.03% | 41.13% |
| iSpecimen Inc. (ISPC)vs › | $2.69M | 1.25% | 22.09% | 37.48% | 43.16% |
| Moleculin Biotech, Inc. (MBRX)vs › | $2.38M | 0.00% | 0.00% | 0.00% | 0.00% |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH)vs › | $2.38M | 0.00% | 0.00% | 0.00% | 0.00% |
| Onconetix, Inc. (ONCO)vs › | $2.37M | 80.40% | 59.71% | -452.13% | -301.42% |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.37M | 0.00% | 0.00% | 0.00% | 0.00% |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.32M | 63.43% | 61.72% | 62.82% | 60.98% |
Gross Margin
23.2%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | -220.77% |
| 2026-03-31 | 22.82% |
| 2025-12-31 | 18.91% |
| 2025-09-30 | 27.00% |
| 2025-06-30 | 19.92% |
| 2025-03-31 | 26.21% |
| 2024-12-31 | 22.28% |
| 2024-09-30 | 38.73% |
| 2024-06-30 | 41.29% |
| 2024-03-31 | 34.61% |
| 2023-12-31 | 18.06% |
| 2023-09-30 | 74.97% |
| 2023-06-30 | 93.75% |
| 2023-03-31 | 90.55% |
| 2022-12-31 | 92.54% |
| 2022-09-30 | 87.30% |
| 2022-06-30 | 88.82% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
